They won't replace any meds, per se. They are in an entirely new class. Rather, they will enable improved function of the CFTR protein (no other drug has achieved this). NaCl movement will improve...secretions won't be as thickened. Mucocilliary movement will be more efficient in clearing mucus in the lungs as mucus won't be as thickened due to the improved NaCl movement. Infections would most likely lessen as the mucus will be more readily cleared from the lungs. This is all speculation at this point...but encouraging trial results thus far....I doubt pancreatic insufficiency will change. I imagine nebulized treatments would occur less frequently, if at all.